Last edition
News about
Lupin Receives Approval from US FDA for Bromfenac Ophthalmic Solution, 0.07%
Lupin is the exclusive first-to-file for this product and is eligible for 180-day exclusivity. The product will be manufactured at Lupin’s Pithampur facility in India.
Pharma Posts End of Year Bounce as CPHI Barcelona Reports Record Attendance
CPHI Barcelona hosted last month in Spain saw a record attendance of 54,000 as pharma confidence returns. The exhibition, which is seen by many as an early indicator of growth in the year ahead, points to the industry having turned a corner with demand expected to accelerate in 2024.
Strides Gets USFDA Approval for Generic Suprep Bowel Prep Kit
The Product has a market size of USD143 Mn per IQVIA. The Product will be manufactured at the company's facility in Bengaluru.
Lupin Launches World's First Fixed-dose Triple Combination Drug
Lupin Vilfuro-G® is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide, for the long-term management and treatment of moderate to severe COPD.
Symbiosis Pharmaceutical Services granted MHRA Licence Following 1Mn Pound Investment
Symbiosis Pharmaceutical Services, has launched new in-house analytical and microbiological capabilities to enable testing of small molecule, biological, and Advanced Therapeutic Medicinal Products (ATMP) biopharmaceuticals following a £1m plus investment.
Batavia Opens GMP Production Facility in the Netherlands
Batavia Biosciences has released Amalia, a GMP-ready manufacturing facility in Bilthoven, Netherlands, expanding capabilities to deliver clinical manufacturing of viral vaccines and viral vectors.
AstraZeneca Pharma Gets Permission to Import Pharmaceutical Formulations of New Drug for Sale
AstraZeneca Pharma India Limited has received permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for the additional indication of Olaparib film coated tablets of 100mg / 150mg (Lynparza).
Lupin Gets Approval from US FDA for Pitavastatin Tablets
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in Adults with primary hyperlipidemia, Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
Chiesi and Haisco Announce Licensing Agreement
HSK31858 is an oral, potent, and highly selective small molecule DPP1 inhibitor currently in Phase 2 trials in China with the potential to be an anti-inflammatory agent in bronchiectasis.
USFDA Gives Nod to Strides Pharma's Generic Drug for Seizures
Strides Pharma Science announced that its subsidiary has received approval from the US health regulator to market a generic medication for seizures.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy